Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
DHA:JHRML'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.7 Med: 1.78 Max: 2.56
Current: 2.56
During the past 5 years, the highest Debt-to-EBITDA Ratio of JMI Hospital Requisite Manufacturing was 2.56. The lowest was 1.70. And the median was 1.78.
DHA:JHRML's Debt-to-EBITDA is ranked worse than 65.33% of 473
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs DHA:JHRML: 2.56
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
JMI Hospital Requisite Manufacturing Debt-to-EBITDA Related Terms
JMI Hospital Requisite Manufacturing Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:JHRML vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, JMI Hospital Requisite Manufacturing's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JMI Hospital Requisite Manufacturing Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JMI Hospital Requisite Manufacturing's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where JMI Hospital Requisite Manufacturing's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
JMI Hospital Requisite Manufacturing (DHA:JHRML) has a Debt-to-EBITDA of 4.33 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on JMI Hospital Requisite Manufacturing. This is 143% above median its historical median of 1.78. Over the past decade, JMI Hospital Requisite Manufacturing's Debt-to-EBITDA has ranged from 1.70 to 2.56. According to the industry distribution chart, JMI Hospital Requisite Manufacturing ranks #309 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 65.3%.
Is JMI Hospital Requisite Manufacturing's Debt-to-EBITDA too high?
JMI Hospital Requisite Manufacturing's current Debt-to-EBITDA of 4.33 is 143% above median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 2.56. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.62. JMI Hospital Requisite Manufacturing's value of 4.33 is 167.3% above this industry median. Based on the distribution chart, JMI Hospital Requisite Manufacturing ranks #309 out of 473 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, JMI Hospital Requisite Manufacturing has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does JMI Hospital Requisite Manufacturing's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JMI Hospital Requisite Manufacturing ranks #309 out of 473 companies for Debt-to-EBITDA. This places JMI Hospital Requisite Manufacturing in the lower half of its industry. The industry median Debt-to-EBITDA is 1.62. JMI Hospital Requisite Manufacturing's value of 4.33 is 167.3% above this benchmark. Historically, JMI Hospital Requisite Manufacturing's own Debt-to-EBITDA has ranged from 1.70 to 2.56 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 1.62, JMI Hospital Requisite Manufacturing has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.62, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JMI Hospital Requisite Manufacturing's current Debt-to-EBITDA of 4.33 is 167.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on JMI Hospital Requisite Manufacturing. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JMI Hospital Requisite Manufacturing's current Debt-to-EBITDA is 4.33, which is 143% above median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JMI Hospital Requisite Manufacturing stock overvalued right now?
Based on GuruFocus' analysis, JMI Hospital Requisite Manufacturing (DHA:JHRML) is currently considered Fairly Valued. The stock's GF Value™ is BDT50.43, compared to a current price of BDT54.80 — trading 8.7% above its estimated fair value. The current Debt-to-EBITDA is 4.33, which is 143% above median its 10-year median of 1.78 and 167.3% above the Medical Devices & Instruments industry median of 1.62. JMI Hospital Requisite Manufacturing's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For JMI Hospital Requisite Manufacturing (DHA:JHRML), the current Debt-to-EBITDA is 4.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JMI Hospital Requisite Manufacturing (DHA:JHRML) Overvalued in 2026?
Based on GuruFocus' analysis, JMI Hospital Requisite Manufacturing stock appears to be overvalued.
The current stock price of BDT54.80 is trading 8.7% above its estimated GF Value™ of BDT50.43.
GuruFocus considers JMI Hospital Requisite Manufacturing to be Fairly Valued.
Key valuation signals for DHA:JHRML:
Debt-to-EBITDA: 4.33 (143% above median its 10-year median of 1.78)
GF Value™: BDT50.43 vs. price of BDT54.80 (8.7% above fair value)
Industry Position: 167.3% above the Medical Devices & Instruments median (#309 of 473)
No single metric tells the full story. See the DHA:JHRML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JMI Hospital Requisite Manufacturing Ltd is engaged in the production of medical devices and components. The company produces health & hospicare products. The products of the company include Surgical Sutures, Surgical Gloves, IV Cannula, Bulk Needles, Blister Film, Infusion Set Components, Disposable Scalpels, Nasal Oxygen Cannulas, Blood Transfusion Sets, Urine Drainage Bags, Scalp Vein Sets, and others.
67GF Score
Get the complete analysis for DHA:JHRML
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:JHRML has been successfully added to your 
